Bio-Techne Co. (NASDAQ:TECH) Shares Sold by Royal London Asset Management Ltd.

Royal London Asset Management Ltd. decreased its position in Bio-Techne Co. (NASDAQ:TECHFree Report) by 0.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 60,866 shares of the biotechnology company’s stock after selling 341 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Bio-Techne were worth $4,696,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Goldman Sachs Group Inc. lifted its holdings in Bio-Techne by 32.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 734,337 shares of the biotechnology company’s stock valued at $56,661,000 after acquiring an additional 181,376 shares during the last quarter. V Square Quantitative Management LLC grew its position in Bio-Techne by 18.6% in the fourth quarter. V Square Quantitative Management LLC now owns 4,094 shares of the biotechnology company’s stock worth $316,000 after buying an additional 641 shares during the last quarter. Polen Capital Management LLC bought a new position in shares of Bio-Techne in the fourth quarter valued at $1,727,000. Harbert Fund Advisors Inc. acquired a new stake in shares of Bio-Techne during the 4th quarter valued at $772,000. Finally, Brown Capital Management LLC boosted its stake in shares of Bio-Techne by 12.4% during the 4th quarter. Brown Capital Management LLC now owns 3,550,990 shares of the biotechnology company’s stock worth $273,994,000 after acquiring an additional 392,986 shares in the last quarter. Institutional investors own 98.95% of the company’s stock.

Bio-Techne Stock Down 1.3 %

Shares of NASDAQ:TECH traded down $1.01 during trading on Friday, reaching $75.87. 787,761 shares of the company traded hands, compared to its average volume of 832,326. Bio-Techne Co. has a 1-year low of $51.79 and a 1-year high of $89.91. The company has a quick ratio of 2.88, a current ratio of 4.08 and a debt-to-equity ratio of 0.19. The firm has a market cap of $11.96 billion, a P/E ratio of 60.21, a price-to-earnings-growth ratio of 9.11 and a beta of 1.29. The firm has a fifty day simple moving average of $74.33 and a 200 day simple moving average of $72.53.

Bio-Techne (NASDAQ:TECHGet Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. Bio-Techne had a return on equity of 13.60% and a net margin of 17.59%. The firm had revenue of $303.43 million during the quarter, compared to analysts’ expectations of $292.36 million. During the same quarter last year, the firm earned $0.47 earnings per share. The business’s revenue for the quarter was up 3.2% on a year-over-year basis. Analysts anticipate that Bio-Techne Co. will post 1.56 earnings per share for the current fiscal year.

Bio-Techne Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 24th. Investors of record on Monday, May 13th were given a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a yield of 0.42%. The ex-dividend date was Friday, May 10th. Bio-Techne’s payout ratio is presently 25.40%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on TECH shares. Citigroup downgraded Bio-Techne from a “buy” rating to a “neutral” rating and set a $85.00 target price for the company. in a report on Wednesday, May 22nd. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Bio-Techne from $85.00 to $82.00 and set a “buy” rating for the company in a research note on Thursday, April 18th. Robert W. Baird lifted their target price on shares of Bio-Techne from $73.00 to $81.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. Finally, Benchmark restated a “buy” rating and issued a $95.00 price target on shares of Bio-Techne in a research report on Thursday, May 2nd. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Bio-Techne has an average rating of “Moderate Buy” and a consensus price target of $81.00.

View Our Latest Stock Report on TECH

Bio-Techne Company Profile

(Free Report)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.

Featured Articles

Institutional Ownership by Quarter for Bio-Techne (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.